Clinical Trial Update: Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time [Phase 3]

View source ↗

Summary

This study reports the completion of a Phase 3 long-term safety evaluation of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in patients requiring …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) (Hydrocodone bitartrate extended-release)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Chronic Pain | Phase 3 | Status: COMPLETED | Results posted: 2017-04-05